Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia

NCT00886496 is registered in ClinicalTrials.gov with Enzon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00886496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00886496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Lead sponsor
Enzon Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2006
Completion date
April 30, 2011
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fever, sweats, and hot flashes, infection, leukemia, lymphoma, myelodysplastic syndromes, neutropenia, unspecified childhood solid tumor, protocol specific